Weekly Conferences | From San Diego to Shanghai: Insilico Medicine showcases new advances in AI-driven drug discovery
Meeting Announcement
Updates every hour. Last Updated: 21-Jun-2026 21:16 ET (22-Jun-2026 01:16 GMT/UTC)
Led by Dr. Alex Zhavoronkov, Founder, CEO, and CBO of Insilico Medicine, the Insilico Medicine team will meet with biopharma partners, investors, and researchers at Booth #4021 to explore collaboration opportunities. Insilico Medicine will showcase the core capabilities of its end-to-end Pharma.AI platform as well as its latest R&D pipeline.
A study by Wake Forest University School of medicine researchers highlights an overlooked issue, “inpatient food insecurity,” or when families don’t have enough to eat while their child is in the hospital because of the hardships that time might create like missed work or additional expenses.
Scientists at IOCB Prague have developed a breakthrough technology that streamlines aptamer development. The new method integrates several biochemical and bioinformatics steps and paves the way for new diagnostic and therapeutic applications. Ongoing applications include wearable sensors that monitor selected biomarkers in real time and provide early warnings of impending health complications. The findings were published in Nature Communications.
Researchers developed a KRAS-driven mouse model of sporadic brain arteriovenous malformation and identified thalidomide as a candidate therapy. In mice, thalidomide improved survival, reduced lesion growth, and stabilized abnormal vessels. In a proof-of-concept clinical study, most evaluable patients showed stable or regressed lesions.